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Although IL-10 down-regulates pro-inflammatory cytokine secretion by hepatic Kupffer cells, the mechanisms underlying its hepatoprotective
effects are not fully clear. This study tested the hypothesis that IL-10 protects the liver against pro-inflammatory cytokines by counteracting their
pro-apoptotic effects. Wild type and IL-10 knockout mice were treated with bacterial lipopolysaccharide and sacrificed 1, 4, 8, and 12 h later.
Plasma ALT activity was measured as a marker of liver injury. Liver pathology and TUNEL response were assessed by histology. Plasma levels
and whole liver mRNA levels were measured for TNF-α, IL-1β, TGF-β1, IL-10, and their respective receptors. Hepatic mRNA levels were
measured for several pro-apoptotic adaptors/regulators, including FasL, Fas receptor, FADD, TRADD, Bad, Bak, Bax, and Bcl-XS, and anti-
apoptotic regulators, including Bcl-w, Bcl-XL, Bcl-2, and Bfl-1. Caspase-3 activity in the liver was determined as well as immunohistochemistry
for IL-1RII, TGF-βRII and Fas receptor. At all time points the livers from IL-10 knockout mice displayed a significantly increased number of
apoptotic nuclei compared to wild type mice. Changes in plasma cytokine levels and their liver mRNA levels were consistent with suppression by
IL-10 of pro-inflammatory cytokine secretion. In addition, pro-inflammatory cytokine receptor mRNA levels (TNF-α, TGF-β, and IL-1β) were
markedly up-regulated by LPS at all time points in IL-10 knockout mice as compared to wild type mice. Expression of the pro-inflammatory
cytokine receptor IL-1RII was similarly increased as shown by immunostaining. The mRNA levels of a typical pro-apoptotic cytokine, TRAIL,
were increased and LPS also up-regulated the mRNA expression of other apoptotic factors to a larger extent in IL-10 knockout mice than in their
wild type counterparts, suggestive of an IL-10 anti-apoptotic effect. In the livers of knockout mice, markedly increased caspase-3 activity was
already evident at the 1-h time point following LPS administration, while in the wild type animals this increase was delayed. Immunostaining also
indicated that LPS increased hepatic expression of the pro-apoptotic receptors Fas and TGF-βRII in IL-10 knockout mice. The data presented in
this study show that: (i) IL-10 modulates not only the secretion of pro-inflammatory cytokines, but also the receptors of these cytokines, and ii) IL-
10 protects the liver against LPS-induced injury at least in part by counteracting pro-inflammatory cytokine-induced liver apoptosis.
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It has become increasingly evident that potent activating
stimuli, such as Gram-negative bacterial lipopolysaccharide
(LPS), induce simultaneous secretion, frequently by the same
cells, e.g., macrophages in different tissues, of two functionally
heterogeneous groups of cytokines: pro-inflammatory, e.g.,
TNF-α, IL-1-α, IL-1β, IL-6, TGF-β and anti-inflammatory,
e.g., IL-10 [1,2]. Under experimental and clinical conditions,⁎ Corresponding author. Fax: +1 859 257 8860.
E-mail address: willem.devilliers@uky.edu (W.J.S. de Villiers).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.12.012the balance seems to be shifted toward a predominant
inflammatory response as a result of the action of pro-
inflammatory cytokines. The biological significance of the
simultaneous secretion of anti-inflammatory cytokines is less
well understood.
Recombinant human IL-10 has been produced and is
currently being tested in clinical trials. This includes rheumatoid
arthritis, inflammatory bowel disease (Crohn's disease), psori-
asis, organ transplantation and chronic hepatitis C [3,4]. IL-10 is
a pleiotropic cytokine which down-regulates the secretion of
pro-inflammatory cytokines by cells in general and especially
inflammatory cells such as liver resident macrophages or
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biological effects of IL-10 on the liver (see review by Le
Moine et al. [6]). IL-10 protects the liver against a number of
injurious agents, such as Gram-negative bacterial LPS and D-
galactosamine [7–9], concanavalin A [10,11], cold-ischemia–
reperfusion [12,13], acetaminophen [14], and CCl4 [15].
Although these conditions are associated with increased liver
apoptosis, a specific role for IL-10 in protecting the liver from
apoptosis has not been investigated. IL-10 protection has been
thought to be primarily mediated by down-regulation of pro-
inflammatory cytokine secretion [8]. However, pro-inflamma-
tory cytokines may be detrimental to the liver by several
mechanisms such as increases in oxidative stress (TNF-α),
apoptosis (TNF-α and TGF-β), mitochondrial dysfunction
(TNF-α) and others, thereby leading to tissue necrosis.
The objectives of this study were thus: (i) to determine the
time course of pro-inflammatory cytokine secretion in IL-10
knockout mice and their wild type counterparts upon stimula-
tion with LPS, and (ii) to establish a link between modulation by
IL-10 of pro-inflammatory cytokine secretion and liver
apoptosis.
2. Materials and methods
2.1. Animals
The experimental protocols were in compliance with the Guide for the Care
and Use of Laboratory Animals (National Research Council, National Academy
Press, Washington, D.C., 1996), as approved by the Institutional Animal Care
and Use Committee of the Veterans Affairs Medical Center, Lexington, KY,
USA.
Male, C57BL/10 mice, weighing 25 g, were purchased from Harlan
Laboratories, Indianapolis, IN. IL-10 knockout C57BL/10 mice were bred in our
animal facility and matched in age with wild type counterparts. Gram-negative
bacterial LPS (Escherichia coli, O26:B6, Sigma Chem Co., St. Louis, MO) was
suspended in sterile saline and injected intraperitoneally in a dose of 1.0
mg≅kg−1 body weight (at a concentration of 0.25 mg≅mL−1). One group of mice
in each of the wild type and IL-10 knockout series received sterile saline only
and were sacrificed 1 h after injection. These mice served as controls to LPS-
injected mice. All animals had free access to food and water throughout the
entire experimental protocol.
2.2. Blood and liver sampling
One, 4, 8 and 12 h after LPS injection, the animals were anesthetized with
Na-pentobarbital (NembutalR; 80 mg≅kg−1 body weight), the abdominal cavity
opened and blood (0.4–0.6 mL) sampled from the exposed inferior vena cava
with the aid of citrate-containing syringes. The liver was flushed with 2–3 mL
ice-cold buffered saline (NaCl 100 mM; HEPES, 20 mM, pH 7.4) through the
portal vein, resected, and blotted on a filter paper. The small left lobe was placed
immediately in 3.5% formalin for histology while the rest of the liver was placed
in liquid nitrogen for biochemical assays. Blood was centrifuged at 13,000×g for
10 min, at 4 °C, and the plasma stored in small aliquots in Eppendorf tubes for
future cytokine assays.
2.3. Biochemical assays
2.3.1. Assay of alanine:2-oxoglutarate aminotransferase (ALT, EC 2.6.1.2)
Immediately after plasma isolation, this enzyme was assayed spectropho-
tometrically with a kit from Sigma Chem. Co. (St. Louis, MO).
Total RNA extraction from the liver was performed using TRIzol reagent
according to the manufacturer's instructions (GIBCO BRL, Life Technologies,
Rockville, MD). The final purification step was performed using Qiagenminicolumns (Qiagen, GmbH, Hilden, Germany) according to the manufac-
turer's instructions.
RNAse protection assay for the determination of mRNA abundance was
performed using templates and reagents from BD Pharmingen (San Diego, CA).
Twenty μg of total RNAwere applied on a lane and gel was run as recommended
by the template and reagent provider. The gels were scanned with the aid of a
Phosphorimager scanner (Molecular Dynamics, Sunnyvale, CA). Optical
density of the bands was quantified using the ImageQuant computer assisted
program (Molecular Dynamics, Sunnyvale, CA). The data are expressed as the
ratio of a specific mRNA band optical density to the band of a housekeeping
gene, L32, a ribosomal protein.
2.3.2. Caspase-3 activity
This was measured with a fluorometric assay using a commercial kit (R&D
Systems, Minneapolis, MN). Briefly, liver extracts were prepared by
homogenization of approximately 100 mg liver tissue with 1 mL lysis buffer
(provided with the kit) followed by sonication (two bursts each of 30 s at 50Ws)
and centrifugation for 30 min at 30,000×g. All operations were performed on ice
or at 4 °C. The supernatant was used for caspase-3 activity assay. The protein
concentration in the reaction mixture was between 0.8 and 1.2 mg. The reaction
was linear versus time at least for 90 min (r2=0.989–0.997).
2.3.3. Protein assay
This was performed using the Bradford procedure with reagents from
BioRad (Hercules, CA) and bovine serum albumin as standard.
2.3.4. Plasma cytokines
These were measured using commercially available kits from R&D Systems,
Minneapolis, MN).
2.4. Liver histology and immunohistochemistry
Hematoxylin–eosin staining was used for histologic assessment of the liver.
The TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling) assay was used to quantify liver apoptosis and was performed using a
kit from Intergen (Purchase, NY) according to the manufacturer's instructions.
Apoptotic nuclei were counted in a blinded fashion in 6 low-magnification fields
for each liver and for 4 livers in each group by two individuals. For
immunohistochemistry slides were deparaffinized in a standard fashion, washed
in PBS, and then microwaved in Retrieval Solution (DAKO, Carpinteria, CA)
for 5 min, washed in PBS, incubated in 0.3% H2O2–methanol solution for 10
min, and then washed again in tap water. Slides were then incubated for 1.5 h at
room temperature in a blocking solution of normal serum, then rinsed and
incubated with primary antibody at 4 °C overnight. Rabbit polyclonal IgG for
FAS and TGFâRII, and rat monoclonal IgG for IL-1RII were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA) and Pharmingen (San Diego, CA)
separately. The Elite ABC kit (Vector Laboratories, Burlingame, CA) was used
with biotinylated secondary antibodies and biotin-conjugated horseradish
peroxidase and was developed with a 3–3′-diaminobenzidine solution per the
manufacturer's instructions. The slides were then counterstained with Dako
Methyl Green (DAKO, Carpinteria, CA).
2.5. Statistics
The results are expressed as mean±standard error of the mean. For
assessment of statistical significance Student's t test was calculated and P≤0.05
was accepted as indicating a significant difference between the compared
groups.
3. Results
3.1. Plasma ALT activity and liver histology
Data depicted in Fig. 1 show higher levels of ALT in the
plasma of IL-10 knockout mice and a significant difference
between the groups was seen at the 8-h time point. There were
Fig. 3. TUNEL response of the liver in a WT, saline-treated mouse (A), and an
IL-10 KO, LPS-treated mouse (B). Animals were sacrificed 12 h after LPS
injection. Note the presence in A of one apoptotic nucleus (arrowhead) which
still maintains its original size. (panel B) Two types of apoptotic nuclei can be
distinguished: large (large arrowheads), approximate in size to non-apoptotic
nuclei and small (small arrowheads) which most likely represent apoptotic
nuclei in the final stage of phagocytosis. Original magnification: ×400.
Numerical data on apoptotic nuclei are presented.
Fig. 1. Effect of LPS treatment on plasma ALT activity in wild type (WT) and
IL-10 knockout (KO) mice. Plotted are mean±S.E.M. (vertical bars) for 5–7
animals in each group. *Pb0.05 versus WT at 8 h. Note that the 0-h time point
represents, here and in subsequent graphs, the values obtained in saline-treated
animals. Abbreviations in this graph will be used throughout the following
figures.
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tion in either wild type or in IL-10 knockout mice (data not
shown).
3.2. Liver TUNEL response
Starting at 4 h after injection, LPS treatment induced a
significant increase in the number of apoptotic nuclei in the
livers of both wild type and IL-10 knockout mice. The effect
was most pronounced in the IL-10 knockout group and reached
a peak at 12 h when 11.8±1.9% of total nuclei appeared
apoptotic (Fig. 2). Representative micrographs illustrating these
effects are presented in Fig. 3. The observation that increased
apoptosis was not associated with markedly increased plasma
ALT activity can be attributed to the following factors. Plasma
ALT activity after intraperitoneal injection of LPS in the dose
used in this study (1 mg/kg b.w.) is not expected to increase
earlier than 24 h after injection. Even then, the increase is
moderate as compared to the increase observed after intrave-
nous injection of same dose of LPS. Furthermore, apoptosis is
not associated with spill-over of the cellular content and theFig. 2. Effect of LPS treatment on the number of apoptotic nuclei in the liver.
Plotted are means±S.E.M. (vertical bars) for 4 animals in each group. *Pb0.05
versus WT, LPS-treated mice. The difference between 0 h time and other time
points was significant (Pb0.05) for both groups, with the exception of the 1-
h time point.degree of apoptosis may not be high enough to lead to
hepatocellular necrosis and would therefore not be associated
with increased ALT.
3.3. Plasma cytokine and liver cytokine and cytokine receptor
mRNA levels
The plasma levels of two pro-inflammatory cytokines, i.e.
TNF-α and IL-1β, and one anti-inflammatory cytokine, IL-10,
were measured. TNF-α in plasma increased significantly in the
wild type mice 1 h after LPS injection and then decreased
toward the basal level at 8 h (Fig. 4). In IL-10 knockout mice,
TNF-α levels were significantly increased at all time points as
compared to both saline-injected animals (zero time point on the
graph) and to wild type animals (Fig. 4). IL-1β displayed
different kinetics from that of TNF-α. A significant increase in
IL-1β levels was first observed at 8 h; levels then declined to the
pre-LPS injection level (zero time point) in the wild type mice,
but continued to increase in IL-10 knockout mice. In the latter
group, similar to TNF-α, the IL-1β levels peaked at 8 h and then
declined (Fig. 4). TNF-α mRNA kinetics closely resembled the
plasma cytokine levels except that the difference between wild
type and IL-10 knockout mice was statistically significant at the
4-h time point only (Fig. 4). IL-1β mRNA increases preceded
that of the cytokine plasma levels and was significantly
Fig. 4. Plasma TNF-α and IL-1β levels and hepatic mRNA expression in WT, LPS-treated and IL-10 KO, LPS-treated mice. Plotted are means±S.E.M. (vertical bars)
for 6 animals in group. *Pb0.05 versus WT group; CK, cytokine.
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of the 1-h time point after LPS injection. The peak of the
increase in IL-1β mRNA also occurred earlier in the wild type
(1 h) than in the IL-10 knockout mice (4 h) (Fig. 4).
IL-10 levels in plasma were, as expected, detected only in
wild type mice and increased to a peak 1 h after LPS treatment
followed by a gradual decline without reaching the pre-LPS
levels (Fig. 5). IL-10 mRNA kinetics resembled plasma IL-10
protein kinetics very closely (Fig. 5).
The kinetics of hepatic mRNA expression levels of TNF-α
and IL-1 receptors are presented in Fig. 6. TNF-α receptor p55
(receptor I) mRNA increased to a plateau 4 h after LPS with
small differences between wild type and IL-10 knockout mice.
A trend to a return to the basal levels was seen in wild type, butFig. 5. Plasma and hepatic mRNA levels of IL-10 in WT, LPS-treated mice.
Plotted are means±S.E.M. (vertical bars) for 6 animals in group. *Pb0.05
versus zero time; **Pb0.05 versus 1 h time point; ***Pb0.05 versus 4 h time
point for both protein and mRNA levels.not in IL-10 knockout mice (Fig. 6). TNF-α receptor p75
(receptor II) mRNA increased significantly only in IL-10
knockout animals and maintained a plateau from 4 to 12 h after
LPS treatment.
IL-1β RI and RII transcripts were increased by LPS
treatment in both wild type and IL-10 knockout mice with the
effect being much more pronounced in the latter group (Fig. 6).
A clear trend to a return to basal levels could again be seen in
wild type mice while in IL-10 knockout mice the increase
reached a plateau that lasted until the 12-h time point (Fig. 6).
Messenger RNA levels of TRAIL, a typical apoptotic ligand
involved in apoptosis following ligation of death receptors,
increased to a peak 4 h after LPS in both wild type and IL-10
knockout mice. Levels decreased to the basal level (at 8 h) in the
wild type mice but not in IL-10 knockout mice (Fig. 7).
Hepatic transcript levels were also measured in this study for
TGF-β1 and its two receptors, RI and RII. This cytokine is a
potent apoptotic signal for hepatocytes [17]. While little or no
effect of LPS could be detected on TGF-β mRNA in the wild
type mice, LPS markedly increased TGF-β mRNA expression
in IL-10 knockout mice to a peak at 8 h followed by some
decrease towards basal levels (Fig. 8). Similar kinetics were
seen for the TGF-βRI and RII transcripts which increased in IL-
10 knockout mice to reach a plateau 4 h after LPS injection;
however, no trend to recovery was evident (Fig. 8).
3.4. Apoptosis adaptors/regulators mRNA expression
RNAse protection assays were performed to examine the
hepatic mRNA expression of apoptotic regulators and adaptors.
The selected apoptotic markers include apoptotic ligands (FasL,
TRAIL), plasma membrane apoptotic receptors (Fas), intracel-
lular adaptors (FADD and TRADD), and several intracellular
Fig. 6. TNF-α and IL-1β receptor mRNA expression in the livers of WT and IL-10 KO, LPS-treated mice. Plotted are means±S.E.M. (vertical bars) for 4 animals in
group. *Pb0.05 versus WT group.
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Bcl-XL and Bfl-1) and pro-apoptotic (Bad, Bak, Bax, and Bcl-
XS) regulators.
LPS treatment increased FasL expression in both wild type
and IL-10 knockout mice with the effect being more
pronounced in the latter. A decrease toward basal levels was
seen only in wild type mice (Fig. 9). Similar kinetics were
observed for Fas receptor expression (Fig. 9). mRNA levels for
two apoptotic adaptors, FADD and TRADD, were up-regulated
by LPS in both wild type and IL-10 knockout mice. The
increase was more evident in the IL-10 knockout group
compared with wild type animals (Fig. 10). LPS treatment
similarly markedly increased the expression of anti-apoptotic
regulators, such as Bcl-XL, Bfl-1 and Bcl-2 in IL-10 knockout
mice but had little or no effect on Bcl-w mRNA (Fig. 11).Fig. 7. Effect of LPS treatment on TRAIL mRNA expression in the liver. Plotted
are means±S.E.M. (vertical bars) for 4 animals in each group. *Pb0.05 versus
WT group.Among pro-apoptotic regulators, LPS affected Bak and Bcl-XS
expression most prominently. Levels were markedly up-
regulated by LPS in IL-10 knockout mice and to a lesser extent
in the wild type mice (Fig. 12). Bax and Bad were also up-
regulated by LPS but there was little or no difference evident
between the wild type and IL-10 knockout animals (Fig. 12).
3.5. Caspase-3 activity and immunohistochemistry
LPS administration increased caspase-3 activity in both IL-
10 knockout and wild type mice (Fig. 13). However, this
increase occurred much earlier in knockout mice and was
already evident at the first 1 h time point after LPS, while in
wild type mice, a significant increase was only seen at 8 h after
LPS injection. At all time points, with the exception of 12 h, the
caspase-3 activity was significantly higher in IL-10 knockout
mice than in the wild type animals (Fig. 13). In agreement with
the mRNA data obtained by RNAse protection assays,
immunohistochemistry showed LPS markedly increased hepat-
ic expression of the pro-inflammatory cytokine receptor IL-
1RII, as well as the pro-apoptotic receptors Fas and TGF-βRII
in IL-10 knockout mice 8 h after administration (Fig. 14).
4. Discussion
This study describes how the absence of IL-10, an important
anti-inflammatory cytokine, increases the response of the liver
to exposure to Gram-negative bacterial LPS in terms of pro-
inflammatory cytokine secretion and liver apoptosis. IL-10
knockout mice served as the animal model and plasma and
mRNA expression levels for pro-inflammatory cytokines and
their receptors were measured. Immunostaining of selected
Fig. 8. TGF-β 2 and TGFβ receptor I and II mRNA expression in the livers of
mice treated with LPS. Plotted are means±S.E.M. (vertical bars) for 4 animals in
a group. *Pb0.05 versus WT group.
Fig. 9. Effect of LPS treatment on hepatic mRNA expression of FasL and Fas
receptor in WT and IL-10 KO mice. Plotted are means±S.E.M. (vertical bars)
for 4 animals in a group. *Pb0.05 versus WT group.
Fig. 10. Effect of LPS treatment on hepatic mRNA expression of FADD and
TRADD in WT and IL-10 KO mice. Plotted are means±S.E.M. (vertical bars)
for 4 animals in each group. For FADD: *Pb0.05 versus WT group; for
TRADD: Pb0.05 versus 0 time point. No statistically significant differences
were observed between the groups.
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cytokines TNF-α and TGF-β are potent apoptotic signals for
liver cells, and their secretion is modulated by IL-10, [16–18].
The apoptotic response of the liver was therefore determined in
this experimental context.
Several studies document the down-regulation of pro-
inflammatory cytokine secretion by IL-10. The secretion of
pro-inflammatory cytokines, measured as either plasma protein
concentration and mRNA level (TNF-α and IL-1β), or as
mRNA level only (TGF-β1) follows a general pattern
consistent with regulation by IL-10 of their respective rates
of synthesis and/or secretion. Higher LPS-induced cytokine
protein and mRNA levels followed by a marked delay in the
return to basal levels are present in IL-10 knockout mice as
compared with their wild type controls. In addition, a
significant increase in plasma and hepatic mRNA IL-10 levels
occur either earlier or simultaneously with those changes seen
in plasma or liver mRNA levels of pro-inflammatory
cytokines. This suggests that much of the kinetics of the latter
may be regulated by IL-10. Our data agree with studies thatshow that IL-10 suppresses the secretion of TNF-α by Kupffer
cells [1]. These cells are probably the most important hepatic
target for IL-10 regulation of pro-inflammatory cytokine
Fig. 11. Effect of LPS treatment on hepatic mRNA expression of anti-apoptotic regulators in WT and IL-10 KO mice. Plotted are means±S.E.M. (vertical bars) for 4
animals in a group. *Pb0.05 between the groups.
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hepatocyte [19,20], sinusoidal endothelial cell [21–23], and
stellate cell [24] also secrete pro-inflammatory cytokines and
their synthesis/secretion may be regulated by IL-10.
An intriguing aspect is the kinetic discrepancy between
plasma levels of TNF-α and IL-1β and their respective mRNAFig. 12. Effect of LPS treatment on hepatic mRNA expression of pro-apoptotic regul
animals in each group. *Pb0.05 between the groups.expression levels in the liver. The kinetics was similar up to 4
h after LPS administration, after which the mRNA levels
declined while plasma levels of the cytokines continued to
increase. Such a kinetic divergence may be explained by
differences in mRNA and protein stability and half-lives as
affected by IL-10 regulation. In addition mRNA expression ofators in WT and IL-10 KO mice. Plotted are means±S.E.M. (vertical bars) for 4
Fig. 13. Effects of LPS on caspase-3 activity in the liver of WT and IL-10 KO
mice. Plotted are means±S.E.M. (vertical bars) for 5–6 animals in each group
and time point. *Pb0.05 between the groups; **Pb0.05 versus 0 time point.
Abbreviations: Casp-, caspase; Fl., fluorescence.
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10. This observation also applied to hepatic protein expression
of the IL-1RII molecule as shown by immunostaining. Down-
regulation of hepatic TNF-α and IL-1β receptor levels may
represent another mechanism whereby IL-10 protects the liver
against pro-inflammatory cytokines. To our knowledge, this
aspect of IL-10 biological activity has not been thus far
described.
LPS-induced pro-inflammatory cytokines have a number of
deleterious effects on the liver, including augmentation of
apoptosis. This establishes a link between the effects of pro-
inflammatory cytokines, IL-10 and liver apoptosis. IL-10 may
protect the liver directly by down-regulating apoptotic cytokine
secretion and indirectly by counteracting the pro-apoptotic
action of pro-inflammatory cytokines.
In this study the augmentation of apoptosis, as judged by the
number of apoptotic nuclei, coincided with the level of caspase-
3 activity in the liver. Caspase-3 is an effector caspase and isFig. 14. Liver immunohistochemistry of WT, LPS-treated (A–C), and IL-10 KO, LPS
TGF-βRII; C,F Fas receptor. Original magnification: ×200.recruited especially when apoptosis is triggered by extrinsic
signals, as seems to happen in the case of LPS. In a recent study
[25] we showed that LPS induces liver apoptosis in rats via
extrinsic signaling, most likely through apoptotic cytokines; as
opposed to alcohol which triggers liver apoptosis mainly via
intrinsic signals. The similar increasing trends in the number of
apoptotic nuclei and the activity of an effector caspase support
the contention that the livers of IL-10 knockout mice have an
enhanced ability to mount an apoptotic response to appropriate
signals. Furthermore, IL-10 may physiologically act as a factor
that opposes apoptosis.
This study shows that the processes of pro-inflammatory
cytokine kinetics and induction of liver apoptosis parallel
each other. It is generally believed that the intracellular
apoptotic machinery is readily available to liver cells to
respond promptly to intracellular or extracellular apoptotic
signals. De novo synthesis of apoptotic proteins may
therefore not be necessary for the liver to mount an apoptotic
response [26,27]. However, apoptotic signals such as
extracellular ligands, e.g., pro-apoptotic cytokines, and their
membrane receptors can be up-regulated in the liver by
deleterious agents such as LPS. Our findings indicate that
pro-apoptotic cytokines such as FasL, TNF-α, TGF-β1 and
TRAIL ligand, and their receptors, i.e., Fas, TNFR p75,
TGF-βRI and RII, were induced by LPS to a significantly
larger extent in IL-10 knockout as compared to wild type
control mice. Immunostaining similarly showed increased
protein expression of Fas and TGF-βRII. We and others
[28,29] have shown previously that Fas receptor and FasL
mRNA are up-regulated in the liver by LPS. While these
results are not conclusive for the regulation by IL-10 of
apoptotic factors, they do indicate a possible link between the
biological action of IL-10 and the apoptotic response of the
liver to extracellular signals, thereby extending prior
knowledge of IL-10 biological activity.-treated mice (D–F), sacrificed 8 h after saline/LPS injection. A, D IL-1RII; B, E
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apoptotic factors, such as adaptors, e.g., FADD and TRADD,
and regulators (both pro- and anti-apoptotic), shows that mRNA
levels changed both in response to LPS and the lack of IL-10. In
agreement with more extensive apoptosis in IL-10 knockout
mice, two pro-apoptotic regulators, Bak and Bcl-XS, were
markedly up-regulated by LPS treatment. It is also interesting to
note that up-regulation of anti-apoptotic factors, i.e. Bcl-XL,
Bcl-2 and Bfl-1, was similarly more accentuated in the IL-10
knockout mice than in their counterparts, even though liver
apoptosis was more evident in IL-10 knockout mice than in the
wild type controls. Up-regulation of antiapoptotic factors/
adaptors during enhanced apoptosis has been observed
previously (e.g., [26]) and can be interpreted as a tendency of
cells to oppose apoptotic death.
In conclusion, our study in IL-10 knockout mice indicates
that: (i) pro- and anti-inflammatory cytokines are secreted
simultaneously upon stimulation with LPS in vivo; (ii) IL-10, an
anti-inflammatory cytokine, markedly inhibits the synthesis and
secretion of a number of pro-inflammatory cytokines and down-
regulates expression of their receptors; and (iii) IL-10 protects
the liver partially by decreasing liver apoptosis. This attenuation
occurs as an end result of the down-regulation of both apoptotic
cytokines and their receptors, rather than through a direct anti-
apoptotic effect on liver cells.
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